A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Healthy Subjects and Patients With Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2019
Price : $35 *
At a glance
- Drugs LY 3372993 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 04 Jun 2019 Status changed from active, no longer recruiting to completed.
- 07 May 2019 Planned number of patients changed from 100 to 36.
- 02 May 2019 Planned End Date changed from 7 Sep 2021 to 14 May 2019.